Search results
Showing 1066 to 1080 of 7707 results
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)
Evidence-based recommendations on botulinum toxin type A (Botox) for preventing headaches in adults with chronic migraine.
Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis and preventing a pulmonary embolism or another deep vein thrombosis in adults.
Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures in adults.
Sotagliflozin with insulin for treating type 1 diabetes (TA622)
Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2 , when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.
Alitretinoin for the treatment of severe chronic hand eczema (TA177)
Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.
Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.
Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)
Evidence-based recommendations on pemetrexed for untreated non-small-cell lung cancer in adults.
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)
Evidence-based recommendations on continuous subcutaneous insulin infusion (insulin pump therapy) for treating type 1 diabetes in adults and children.
Evidence-based recommendations on entecavir for treating chronic hepatitis B in adults.
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (TA148)
NICE is unable to recommend the use in the NHS of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small-cell lung cancer (other than predominantly squamous cell histology) because no evidence submission was received from the manufacturer or sponsor of the technology.
Show all sections
Sections for TA148
Evidence-based recommendations on structural neuroimaging in people with first-episode psychosis.
Evidence-based recommendations on rituximab for treating relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma in adults.
NICE is unable to recommend the use in the NHS of carmustine implants as an adjunct to surgery in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated because no evidence submission was received from the manufacturer or sponsor of the technology. We will review this decision if the company decides to make a submission
Show all sections
Sections for TA149
Pemetrexed for the treatment of non-small-cell lung cancer (TA124)
Evidence-based recommendations on pemetrexed for treating non-small-cell lung cancer in adults.
Stapled haemorrhoidopexy for the treatment of haemorrhoids (TA128)
Evidence-based recommendations on stapled haemorrhoidopexy for treating haemorrhoids in adults.